(2011) A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage
On the contrary, Bacteroides , Parabacteroides , FP , Clostridium leptum , and Prevotella were significantly decreased, and there was a 50% reduction in the high butyrate producer FP (205)
The product is verified to have a purity level of>99%, confirmed through independent third-party testing
Are Barrier and InfiniWell simply legal BPC-157 companies
Lead Researcher Spotlight Professor Predrag Sikiric, MD, PhD (BPC-157 Primary Investigator) Department of Pharmacology University of Zagreb School of Medicine, Zagreb, Croatia Professor Predrag Sikiric has been the primary investigator for BPC-157 research since the 1990s, leading the team that isolated and characterized this peptide from human gastric juice